Rhumbline Advisers Lexicon Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

A detailed history of Rhumbline Advisers transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 152,785 shares of LXRX stock, worth $198,620. This represents 0.0% of its overall portfolio holdings.

Number of Shares

152,785

Previous 134,845 13.3%

Holding current value

$198,620

Previous $323,000 20.74%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$1.54 - $2.28 $27,627 - $40,903	17,940 Added 13.3%	152,785 $256,000
Q1 2024 May 09, 2024	BUY	$1.3 - $3.58 $5,920 - $16,303	4,554 Added 3.5%	134,845 $323,000
Q3 2023 Nov 09, 2023	SELL	$1.06 - $2.33 $10,023 - $22,032	-9,456 Reduced 6.77%	130,291 $142,000
Q2 2023 Aug 08, 2023	BUY	$2.15 - $3.49 $31,564 - $51,236	14,681 Added 11.74%	139,747 $320,000
Q1 2023 May 11, 2023	BUY	$1.99 - $2.68 $11,838 - $15,943	5,949 Added 4.99%	125,066 $304,000
Q4 2022 Feb 14, 2023	BUY	$1.8 - $2.56 $10,299 - $14,648	5,722 Added 5.05%	119,117 $228,000
Q3 2022 Nov 10, 2022	BUY	$1.94 - $3.43 $30,894 - $54,622	15,925 Added 16.34%	113,395 $272,000
Q2 2022 Aug 11, 2022	BUY	$1.31 - $2.69 $22,972 - $47,171	17,536 Added 21.94%	97,470 $181,000
Q1 2022 May 12, 2022	SELL	$1.95 - $3.89 $13,115 - $26,164	-6,726 Reduced 7.76%	79,934 $167,000
Q4 2021 Feb 10, 2022	BUY	$3.81 - $6.16 $10,168 - $16,441	2,669 Added 3.18%	86,660 $341,000
Q3 2021 Nov 12, 2021	BUY	$3.38 - $5.35 $7,432 - $11,764	2,199 Added 2.69%	83,991 $404,000
Q2 2021 Aug 05, 2021	BUY	$4.12 - $5.87 $110,061 - $156,811	26,714 Added 48.5%	81,792 $375,000
Q1 2021 May 06, 2021	SELL	$3.45 - $9.09 $5,557 - $14,643	-1,611 Reduced 2.84%	55,078 $323,000
Q4 2020 Feb 10, 2021	BUY	$1.05 - $3.67 $6,856 - $23,965	6,530 Added 13.02%	56,689 $194,000
Q3 2020 Nov 12, 2020	SELL	$1.44 - $2.1 $21,206 - $30,926	-14,727 Reduced 22.7%	50,159 $72,000
Q2 2020 Aug 13, 2020	BUY	$1.75 - $2.3 $14,488 - $19,041	8,279 Added 14.63%	64,886 $129,000
Q1 2020 May 06, 2020	SELL	$1.8 - $4.28 $6,300 - $14,980	-3,500 Reduced 5.82%	56,607 $110,000
Q4 2019 Feb 05, 2020	BUY	$3.16 - $5.15 $4,294 - $6,998	1,359 Added 2.31%	60,107 $249,000
Q3 2019 Oct 23, 2019	SELL	$1.2 - $6.66 $480 - $2,664	-400 Reduced 0.68%	58,748 $177,000
Q2 2019 Aug 14, 2019	BUY	$5.35 - $7.11 $19,350 - $25,716	3,617 Added 6.51%	59,148 $372,000
Q1 2019 May 01, 2019	SELL	$4.36 - $7.94 $7,246 - $13,196	-1,662 Reduced 2.91%	55,531 $309,000
Q4 2018 Jan 31, 2019	BUY	$6.15 - $10.51 $113,012 - $193,131	18,376 Added 47.34%	57,193 $380,000
Q3 2018 Nov 07, 2018	SELL	$10.32 - $13.06 $28,689 - $36,306	-2,780 Reduced 6.68%	38,817 $414,000
Q2 2018 Aug 06, 2018	BUY	$7.8 - $13.69 $10,561 - $18,536	1,354 Added 3.36%	41,597 $499,000
Q1 2018 May 02, 2018	SELL	$7.86 - $11.39 $10,807 - $15,661	-1,375 Reduced 3.3%	40,243 $345,000
Q4 2017 Feb 09, 2018	SELL	$8.77 - $12.28 $80,447 - $112,644	-9,173 Reduced 18.06%	41,618 $411,000
Q3 2017 Nov 06, 2017	BUY	$12.17 - $16.3 $618,126 - $827,893	50,791	50,791 $624,000

Others Institutions Holding LXRX

# of Institutions

131

Shares Held

240M

Call Options Held

617K

Put Options Held

286K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $245M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Lexicon Pharmaceuticals, Inc. Transaction History